AFFLUENT MEDICAL
Affluent Medical
Affluent Medical : Financial communication schedule for the second half of 2021
13-Jul-2021 / 17:51 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
PRESS RELEASE
Aix-en-Provence, 13 July 2021 - 17.45 p.m.
Financial communication schedule
for the second half of 2021
Affluent Medical (code ISIN: FR0013333077 - Ticker: AFME), a French medtech specialising in the international
development and industrial scale-up of innovative medical prostheses, at a clinical stage, to treat urinary
incontinence and cardiac mitral valve pathology, today announces the date of publication of its 2021 half year results
(audited) and its participation in two broker forums:
? Publication of the 2021 half year results (audited): September 22, 2021, after the close of trading
? Participation in the Investor Access forum, Paris: September 27 & 28, 2021
? Participation in the Midcap Event forum, Paris: October 21 & 22, 2021
About Affluent Medical
Affluent Medical is a French MedTech company founded by Truffle Capital with the ambition to become a world leader in
the treatment of heart and vascular diseases, which are the world's leading cause of death, and of urinary
incontinence, which today affects one in four adults. Affluent Medical develops innovative, next-generation minimally
invasive implants to restore key physiological functions in these areas. The company's four major technologies are
currently in preclinical and clinical phases. A first medical device is expected to be launched by 2023 with Kalios in
Europe.
For more information: www.affluentmedical.com
Contacts :
AFFLUENT MEDICAL ACTIFIN, financial communication
Jérôme Geoffroy Ghislaine Gasparetto
Chief Financial Officer +33 (0)1 86 26 68 17
investor@affluentmedical.com affluentmedical@actifin.fr
ACTIFIN, financial press relations DGM, corporate press relations
Jennifer Jullia Thomas Roborel de Climens
+33 (0)6 47 97 54 87 +33 (0)6 14 50 15 84
jjullia@actifin.fr thomasdeclimens@dgm-conseil.fr ----------------------------------------------------------------------------------------------------------------------- Regulatory filing PDF file File: Financial communication schedule for the second half of 2021
=-------------------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Inside information / Issuer activities (acquisitions, sales...)
EQS News ID: 1218475
End of Announcement EQS News Service
=------------------------------------------------------------------------------------ 1218475 13-Jul-2021 CET/CEST
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1218475&application_name=news(END) Dow Jones Newswires
July 13, 2021 11:52 ET (15:52 GMT)
